Dna X annual free cash flow
2018
2019
2020
2021
2022
2023
2024
Dna X Free Cash Flow (FCF) History (SONM)
Dna X reported −$8.7M in free cash flow for fiscal 2024, a decrease of $4.6M from the previous fiscal year, with a free cash flow margin of −17.09%.
View full Dna X company overviewDna X free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$8.7M | −$4.6M | — | −17.09% |
| 2023 | 2023-12-31 | −$4.1M | $8.3M | — | −4.37% |
| 2022 | 2022-12-31 | −$12.4M | $26.2M | — | −17.71% |
| 2021 | 2021-12-31 | −$38.5M | −$28.0M | — | −70.59% |
| 2020 | 2020-12-31 | −$10.6M | $23.9M | — | −16.52% |
| 2019 | 2019-12-31 | −$34.5M | −$37.6M | — | −29.69% |
| 2018 | 2018-12-31 | $3.1M | — | — | +2.27% |
Dna X quarterly free cash flow
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.22
Q2.22
Q3.22
Q4.22
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | −$4.5M | −$4.2M | — | −29.59% |
| Q3 2024 | 2024-09-30 | −$554,000 | $1.7M | — | −3.69% |
| Q2 2024 | 2024-06-30 | −$3.4M | $6.9M | — | −29.79% |
| Q1 2024 | 2024-03-31 | −$198,000 | −$960,000 | — | −2.17% |
| Q3 2023 | 2023-09-30 | −$305,000 | $307,000 | — | −1.11% |
| Q4 2022 | 2022-12-31 | −$2.2M | $7.8M | — | −9.23% |
| Q3 2022 | 2022-09-30 | −$10.3M | −$3.9M | — | −50.22% |
| Q2 2022 | 2022-06-30 | $762,000 | −$3.8M | −83.36% | +6.37% |
| Q1 2022 | 2022-03-31 | −$612,000 | −$1.5M | — | −4.62% |
| Q4 2020 | 2020-12-31 | −$10.0M | −$5.2M | — | −63.42% |
| Q3 2020 | 2020-09-30 | −$6.4M | −$11.7M | — | −44.34% |
| Q2 2020 | 2020-06-30 | $4.6M | $35.0M | — | +21.74% |
| Q1 2020 | 2020-03-31 | $891,000 | $5.5M | — | +7.01% |
| Q4 2019 | 2019-12-31 | −$4.8M | −$10.4M | — | −27.98% |
| Q3 2019 | 2019-09-30 | $5.3M | $2.7M | +100.53% | +18.44% |
| Q2 2019 | 2019-06-30 | −$30.4M | −$30.0M | — | −69.54% |
| Q1 2019 | 2019-03-31 | −$4.6M | $139,000 | — | −17.41% |
| Q4 2018 | 2018-12-31 | $5.6M | — | — | +11.96% |
| Q3 2018 | 2018-09-30 | $2.7M | — | — | +6.72% |
| Q2 2018 | 2018-06-30 | −$393,000 | — | — | −1.25% |
| Q1 2018 | 2018-03-31 | −$4.7M | — | — | −26.11% |
Dna X free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$34.5M to −$8.7M, a net increase of $25.8M. Dna X's latest reported quarter, Q4 2024, generated −$4.5M in free cash flow, a decrease of $4.2M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Dna X filings at SEC.gov ↗